Mayo loses patent battle
It looks like Mayo Clinic lost its legal dispute with Prometheus Labs over the patenting of standards for a diagnostic test.
This is a deal that went to the Supreme Court about six months ago. It involves Mayo's legal tiff with a researcher that used to work in Roch.
Some experts say this ruling could be a game changer.
Here's some from a Reuters piece on it.
_________________
Medical tests can be patented, a U.S. appeals court ruled in its first decision on the issue since a landmark Supreme Court case six months ago on business-method patents. Prometheus Laboratories Inc.’s method of determining the dosage of medicines to treat stomach diseases can be patented, the U.S. Court of Appeals for the Federal Circuit in Washington said.
Closely held Prometheus had lost a lower court case in which it sued the Mayo Clinic for infringing two patents. The Federal Circuit reversed the ruling in 2009 and today upheld its decision, saying a judge erred in ruling the patents invalid.
The ruling may aid companies including Myriad Genetics Inc. and Novartis AG, which have tried to capitalize on burgeoning demand for “personalized medicine,” where doctors determine if a patient is genetically susceptible to a particular disease or would be more responsive to certain medicines.
Interest in such testing has grown partly as health-benefit companies including Medco Health Solutions Inc. see a way to trim costs. “It’s a tremendous advance in the whole world of pharmaceuticals if you can better match people with the medicines you give them,” said Jennifer Gordon, a lawyer at Baker Botts in New York who submitted a filing in the case on behalf of Novartis. Companies “want the full capability of getting any type of patent that covers their technology. Patents have been very important to this industry.” Myriad, which is appealing a federal judge’s ruling in a separate case that invalidated its patents on a test for breast cancer, rose 74 cents, or 3.2 percent, to $23.71 at 4 p.m. New York time in Nasdaq Stock Market composite trading. Diagnostic Industry Boost The Prometheus case was being watched to see how the court would interpret a June ruling from the Supreme Court that considered what types of innovations would qualify for legal protection. The Federal Circuit specializes in U.S. patent law. “The court of appeals is fairly strongly of the view that methods of treatment and methods of diagnostics are patentable all the time,” said Nick Groombridge, a lawyer at Weil, Gotshal in New York.

Recent Comments